scholarly journals Carcinoma Epidermoide Cutáneo, enfermedad de alta relevancia mundial

2021 ◽  
Vol 6 (11) ◽  
pp. e731
Author(s):  
José Roberto Hernández Chacón ◽  
Sheirys Arleth Torres Morales ◽  
Evelyn María Hernández Chacón
Keyword(s):  
Carcinoma In Situ ◽  
De Novo ◽  
Carcinoma Epidermoide

El carcinoma epidermoide cutáneo (CEC), antiguamente llamado carcinoma espinocelular o escamoso se define como el tumor primario de la piel que expresa una diferenciación descamativa predominante. Suele aparecer a partir de lesiones precursoras, como la queratosis actínica o la enfermedad de Bowen (carcinoma in situ), aunque también puede aparecer en pieles irradiadas o sobre lesiones inflamatorias crónicas o de novo, tales como en cicatrices de quemaduras, úlceras en miembros inferiores y en casos de micosis profundas; así como en zonas de alto y medio riesgo de la cabeza y cuello. Tiene una incidencia hasta tres veces mayor en hombres que en mujeres, y se presenta principalmente entre las edades de 64 a 76 años.  Es la segunda causa de muerte por cáncer cutáneo después del melanoma. Forma parte de los cánceres cutáneos no melanocíticos y se considera uno de los cánceres más frecuentes en la población de piel blanca a nivel mundial, por lo que el tener tipo de piel I o II según la clasificación Fitzpatrick y el tener labores al aire libre tales como agricultura y construcción, aumentan el riesgo de padecer la enfermedad. El diagnóstico definitivo del CEC se establece mediante biopsia de la lesión y examen con histopatología. La cirugía representa el tratamiento de elección y la técnica de Mohs se considera la técnica de elección.

scholarly journals Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?

2018 ◽  
Vol 13 (9) ◽  
Author(s):  
Hanan Goldberg ◽  
Douglas C. Cheung ◽  
Thenappan Chandrasekar ◽  
Zachary Klaassen ◽  
Christopher J.D. Wallis ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Carcinoma In Situ ◽  
De Novo ◽  
Cox Model ◽  
Univariate Analysis ◽  
Upper Tract Urothelial Carcinoma ◽  
Specific Mortality ◽  
Cancer Specific Mortality ◽  
Bladder Recurrence

Introduction: Upper tract urothelial carcinoma (UTUC) accounts for <5% of all urothelial cancers. We aimed to ascertain the clinical differences between UTUC tumours presenting de novo (DnUTUC) and those presenting secondary (SUTUC) following a bladder cancer diagnosis. Methods: Our institutional database was queried for all UTUC patients who were surgically treated with radical nephroureterectomy or ureterectomy between 2003 and 2017. Bladder recurrence and cancer-specific mortality were compared. To reduce the possible bias due to confounding variables obtained from a simple comparison of outcomes, DnUTUC patients were matched (for age, gender, tumour location, type of surgery, grade, TNM staging, presence of carcinoma in situ, and lymphovascular invasion) with propensity score to SUTUC patients. Bladder recurrence and cancer-specific mortality were assessed with Cox proportional hazards model. Results: A total of 117 UTUC patients were identified: 80 with DnUTUC (68.4%) and 37 with SUTUC (31.6%). A greater proportion of males with SUTUC was demonstrated (89.2% vs. 68.8; p=0.02). In both groups, 67.5% of patients had high-grade disease, but SUTUC demonstrated a higher carcinoma in situ rate (43.2% vs. 25%; p=0.047). Univariate analysis demonstrated that the five-year bladder recurrence rate was trending to be higher in SUTUC (65.3% vs. 20.5%; p=0.099). In the Cox model, however, it was associated with increased bladder recurrence (hazard ratio [HR] 3.69; 95% confidence interval [CI] 1.68–8.09; p=0.001). Although univariate analysis demonstrated that SUTUC patients were more likely to die of their disease (30.6% vs. 9%; p=0.009), the multivariable Cox model did not demonstrate this association. The limitations of this study include its retrospective, single-centre design and relatively small cohort of patients. Conclusions: In this hypothesis-generating study, some evidence suggests that further research is needed to delineate differences between SUTUC and DnUTUC.

scholarly journals De-novo acute myeloid leukemia in a BRCA positive female with locally treated ductal carcinoma In Situ

2021 ◽  
Vol 15 ◽  
pp. 100237
Author(s):  
Edward Nabrinsky ◽  
Faisal Masood ◽  
Sufyan AbdulMujeeb ◽  
Nahren Asado ◽  
Imad Almanaseer ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Myeloid Leukemia ◽  
De Novo ◽  
Ductal Carcinoma ◽  
Acute Myeloid

scholarly journals Pathological Characteristics of Primary Bladder Carcinoma Treated at a Tertiary Care Hospital and Changing Demographics of Bladder Cancer in Sri Lanka

2016 ◽  
Vol 2016 ◽  
pp. 1-6
Author(s):  
S. Sasikumar ◽  
K. S. N. Wijayarathna ◽  
K. A. M. S. Karunaratne ◽  
U. Gobi ◽  
A. Pathmeswaran ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Sri Lanka ◽  
Bladder Carcinoma ◽  
Carcinoma In Situ ◽  
De Novo ◽  
Tertiary Care ◽  
Care Hospital ◽  
High Grade ◽  
Female Ratio

Objectives. The aim was to compare demographics and pathological features of bladder carcinoma treated in a urology unit with findings of previous studies done in Sri Lanka.Materials and Methods. Data of newly diagnosed patients with bladder cancer in a tertiary referral centre from 2011 to 2014 were analysed. Data on bladder cancers diagnosed from 1993 to 2014 were obtained from previous publications and Sri Lanka Cancer Registry.Results. There were 148 patients and mean age was 65 years. Male to female ratio was 4.1 : 1. Urothelial carcinoma (UC) was found in 89.2% of patients. Muscle invasion was noted in 35% of patients compared to 48.4% two decades ago. In patients with UC, 16.5% were found to have pT1high grade tumour. It was 5.3% from 1993 to 2000. Pure squamous cell carcinoma was found in 8.1% of patients while primary or de novo carcinoma in situ (not associated with high grade pT1tumours) was seen in one patient only.Conclusions. The percentage of squamous carcinoma is higher among Sri Lankan patients while primary carcinoma in situ is a rarity. The percentage of muscle invasive disease has decreased while the percentage of pT1high grade tumours has increased during the last two decades in Sri Lanka.

1252: Impact of Concomitant Carcinoma in situ on Clinical Outcomes after Radical Cystectomy

2006 ◽  
Vol 175 (4S) ◽  
pp. 403-403 ◽  
Author(s):  
Shahrokh F. Shariat ◽  
Ganesh S. Palapattu ◽  
Gilad E. Amiel ◽  
Pierre I. Karakiewicz ◽  
Craig G. Rogers ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Radical Cystectomy ◽  
Carcinoma In Situ

Prognoseverbesserung beim DCIS: Weniger invasive Rezidive durch adjuvante Therapien

2011 ◽  
Vol 02 (03) ◽  
pp. 110-110
Author(s):  
Katharina Arnheim
Keyword(s):  
Carcinoma In Situ

Patientinnen mit duktalem Carcinoma in situ (DCIS) müssen nicht mastektomiert werden; sie haben auch nach brusterhaltender Operation ein günstiges Outcome. Eine weitere Prognoseverbesserung wird durch Nachbestrahlung und adjuvante Tamoxifen-Gabe erreicht.

Sign in / Sign up

Export Citation Format

Share Document